factive- gemifloxacin mesylate tablet
merus labs international inc. - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - gemifloxacin 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies. ) acute bacterial exacerbation of chronic bronchitis (abecb) caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . because fluoroquinolones, including factive, have been associated with serious adverse reactions (see warnings ) and for some patients abecb is self-limiting, reserve factive for treatment of abecb in patients who have no alternative treatment options. community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant s
factive- gemifloxacin mesylate tablet
vansen pharma inc. - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - gemifloxacin 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies . ) acute bacterial exacerbation of chronic bronchitis caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant streptococcus pneumoniae , includes isolates previously known as prsp (penicillin-resistant streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (mic ≥2 μg/ml), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. to reduce the development
factive 320mg f.c. tablets film-coated tablet
tabuk pharmaceutical manufacturing company, saudi arabia - gemifloxacin mesilate - film-coated tablet - 320 mg
factive 320mg f.c. tablets film-coated tablet
tabuk pharmaceutical manufacturing company, saudi arabia - gemifloxacin mesilate - film-coated tablet - 320 mg
factive film-coated tablet 320 mg
pahang pharmacy sdn. bhd. - gemifloxacin mesylate -
factive- gemifloxacin mesylate tablet
oscient pharmaceuticals - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - tablet - 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies . ) acute bacterial exacerbation of chronic bronchitis caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant streptococcus pneumoniae , includes isolates previously known as prsp (penicillin-resistant streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (mic ≥2 μg/ml), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. to reduce the development
factive
glaxosmithkline nz limited - gemifloxacin mesilate sesquihydrate 426.39mg equivalent to 320 mg gemifloxacin pure free base; - film coated tablet - 320 mg - active: gemifloxacin mesilate sesquihydrate 426.39mg equivalent to 320 mg gemifloxacin pure free base excipient: crospovidone hypromellose macrogol 4000 macrogol 6000 magnesium stearate microcrystalline cellulose povidone titanium dioxide
factive tablet
oscient pharmaceuticals corporation - gemifloxacin (gemifloxacin mesylate) - tablet - 320mg - gemifloxacin (gemifloxacin mesylate) 320mg - quinolones
factive ®
aspen-p -
factive tablet
gemifloxacin 320mg